Daily Endocrinology Research Analysis
Three impactful endocrinology studies stood out: mechanistic insights into how tirzepatide promotes weight loss (increased fat oxidation without attenuating metabolic adaptation in humans), a massive Mexican cohort linking prediabetes to excess all-cause, cardiovascular, renal, and acute diabetic mortality, and a multinational real-world analysis suggesting GLP-1 receptor agonists reduce retinal vein occlusion risk versus DPP-4 inhibitors. Together, they span basic-to-clinical translation in obe
Summary
Three impactful endocrinology studies stood out: mechanistic insights into how tirzepatide promotes weight loss (increased fat oxidation without attenuating metabolic adaptation in humans), a massive Mexican cohort linking prediabetes to excess all-cause, cardiovascular, renal, and acute diabetic mortality, and a multinational real-world analysis suggesting GLP-1 receptor agonists reduce retinal vein occlusion risk versus DPP-4 inhibitors. Together, they span basic-to-clinical translation in obesity/diabetes and inform prevention and therapeutic choices.
Research Themes
- Obesity pharmacotherapy mechanisms and energy metabolism
- Prediabetes as a driver of premature mortality
- Cardiometabolic therapies and microvascular ocular outcomes
Selected Articles
1. Adipose Tissue Macrophages in Metabolic Dysfunction-Associated Steatohepatitis Secrete Extracellular Vesicles That Activate Liver Fibrosis in Obese Male Mice.
In obese male mice with MASH, adipose tissue macrophages secrete small extracellular vesicles enriched in miR-155 and miR-34a that downregulate Pparg, activate hepatic stellate cells, and exacerbate liver fibrosis. Anti-inflammatory macrophage sEVs ameliorate fibrosis, while miRNA-depleted sEVs lose effect and antagomirs to miR-155/miR-34a block activation, establishing causal roles and a mechanistic extrahepatic signal.
Impact: This work identifies a mechanistic adipose–liver communication axis driving fibrosis in MASH and pinpoints fibrogenic miRNAs in macrophage sEVs as potential therapeutic targets.
Clinical Implications: Although preclinical, targeting ATM phenotypes or their sEV miRNA cargo (e.g., miR-155/miR-34a) could represent novel anti-fibrotic strategies for MASH, complementing metabolic therapies.
Key Findings
- MASH adipose tissue macrophages secrete sEVs enriched in miR-155 and miR-34a that downregulate Pparg and activate hepatic stellate cells.
- Administration of MASH-ATM sEVs exacerbated liver fibrosis in obese mice, whereas anti-inflammatory macrophage sEVs mitigated fibrosis.
- miRNA-depleted (Dicer knockdown) sEVs lost profibrotic activity, and miR-155/miR-34a antagomirs blocked stellate cell activation, confirming causality.
Methodological Strengths
- Integrated in vitro and in vivo models with nanoparticle tracking and flow cytometry to characterize sEVs and macrophage phenotypes.
- Mechanistic causality tested using Dicer knockdown to deplete sEV miRNAs and antagomirs against miR-155/miR-34a.
Limitations
- Findings are in obese male mice; human validation is lacking.
- The specific dosing, kinetics, and safety of targeting sEV miRNAs were not evaluated clinically.
Future Directions: Validate ATM-sEV signatures and miR-155/miR-34a effects in human MASH, and develop targeted delivery or macrophage reprogramming approaches to modulate sEV cargo.
BACKGROUND & AIMS: Given the need for effective interventions in metabolic dysfunction-associated steatohepatitis (MASH), understanding the role of adipose tissue macrophage (ATM)-derived small extracellular vesicles (sEVs) is important. We aimed to evaluate the contribution of MASH-ATM-sEVs to the development of liver fibrosis in obese male mice. METHODS: Using flow cytometry and nanoparticle tracking analysis, we characterized MASH-ATMs and their secreted sEVs. We assessed the fibrogenic effects of sEVs from MASH-ATMs or anti-inflammatory macrophages on stellate cells in vitro and in mice in vivo. In addition, we isolated Dicer knockdown microRNA (miRNA)-depleted sEVs from MASH-ATMs and cotreated stellate cells with MASH-ATM-sEVs and miR-155 or miR-34a antagomirs. RESULTS: MASH-ATMs exhibited a pro-inflammatory and lipid-associated phenotype, secreting sEVs enriched in the fibrogenic miRNAs, miR-155 and miR-34a, which also down-regulate Pparg. In vitro, MASH-ATM-sEVs induced hepatic stellate cell activation and fibrogenesis and exacerbated liver fibrosis when administered to obese mice. In addition, anti-inflammatory macrophage sEVs mitigated fibrosis both in vitro and in vivo. miRNA-free Dicer knockdown-MASH-ATM-sEVs were without effects and cotreatment with miR-155/miR-34a antagomirs blocked the effects of MASH-ATM-sEVs to induce hepatic stellate cell activation. CONCLUSIONS: This study demonstrated the role of MASH-ATM-sEVs in promoting liver fibrosis in obesity. Identification of the fibrogenic miRs, miR-155, and miR-34a, within MASH-ATM-sEVs, highlights the mechanistic importance of extrahepatic signals in MASH. These findings showed the therapeutic potential of modulating macrophage phenotypes and their sEV cargo to ameliorate MASH.
2. Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation.
In calorie-restricted obese mice, tirzepatide attenuated metabolic adaptation and increased fat oxidation. In a phase 1 trial in people with obesity, tirzepatide increased fat oxidation and reduced appetite and ad libitum energy intake versus placebo, but did not measurably attenuate metabolic adaptation, clarifying mechanism-of-action across species.
Impact: Clarifies how tirzepatide drives weight loss—via increased fat oxidation and appetite reduction—informing counseling, combination strategies, and translational models for anti-obesity pharmacotherapy.
Clinical Implications: Clinicians can emphasize substrate utilization shifts and appetite suppression rather than reduced metabolic adaptation when counseling on tirzepatide; pairing with lifestyle strategies targeting energy expenditure may optimize outcomes.
Key Findings
- In obese mice, tirzepatide attenuated the drop in energy expenditure seen with calorie restriction and lowered respiratory exchange ratio, indicating increased fat oxidation.
- In humans with obesity (phase 1), tirzepatide increased fat oxidation and reduced appetite and ad libitum caloric intake compared with placebo.
- No measurable attenuation of metabolic adaptation was detected in humans despite increased fat oxidation, highlighting species differences and mechanistic nuance.
Methodological Strengths
- Translational design integrating preclinical models with a placebo-controlled phase 1 human study.
- Direct metabolic phenotyping (indirect calorimetry, respiratory exchange ratio, ad libitum meal tests).
Limitations
- Phase 1 human study with small sample size and short, acute metabolic assessments.
- Energy expenditure findings differ between species; long-term clinical relevance requires further trials.
Future Directions: Test long-term effects on energy expenditure and substrate utilization in larger randomized trials, and evaluate combination strategies (e.g., exercise) to counter metabolic adaptation.
Tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, promoted significant body weight reduction in the phase 3 clinical trials. We conducted a preclinical study and a phase 1 clinical trial (NCT04081337) to understand potential mechanisms mediating tirzepatide-induced weight loss in mice and people with obesity. In calorie-restricted, obese mice, chronic treatment with tirzepatide reduced the drop in energy expenditure that occurred in vehicle-treated and pair-fed mice, indicating that tirzepatide attenuated metabolic adaptation. Respiratory exchange ratio also decreased in tirzepatide-treated mice, indicating increased fat oxidation. In the clinical trial, tirzepatide appeared to have no impact on metabolic adaptation but led to increased fat oxidation and reductions in appetite and calorie intake during an ad libitum test meal (vs. placebo). This is the first study to provide insights into the mechanisms of action of tirzepatide on weight loss with respect to calorie intake, energy expenditure, and macronutrient utilization.
3. Prediabetes and Risk of All-Cause and Cause-Specific Mortality: A Prospective Study of 114 062 Adults in Mexico City.
In 114,062 Mexican adults followed for a median of 18.4 years, ADA- and IEC-defined prediabetes were associated with elevated all-cause, cardiovascular, renal, and acute diabetic mortality at ages 35–74. Absolute excess risks were substantial (e.g., 7% of cardiovascular and 31% of acute diabetic deaths attributable to ADA-defined prediabetes), with adiposity explaining part of the excess.
Impact: Provides region-specific, long-term evidence quantifying mortality burden from prediabetes, informing prevention policies and risk stratification in Latin America and beyond.
Clinical Implications: Supports early identification and management of prediabetes (particularly in individuals with adiposity) to reduce premature mortality; emphasizes integrating HbA1c screening and lifestyle/weight management in primary care.
Key Findings
- Prediabetes (ADA-defined) was associated with all-cause mortality RR 1.13 (1.07–1.20) and IEC-defined with RR 1.27 (1.17–1.38) at ages 35–74.
- Cardiovascular, renal, and acute diabetic deaths were all elevated; for ADA-defined prediabetes, attributable fractions were 7% (cardiovascular), 9% (renal), and 31% (acute diabetic).
- Excess mortality risks were partly explained by adiposity, indicating modifiable pathways.
Methodological Strengths
- Very large prospective cohort with long median follow-up (18.4 years) and cause-specific mortality assessment.
- Use of both ADA and IEC HbA1c definitions with multivariable adjustment and estimation of attributable fractions.
Limitations
- Observational design susceptible to residual confounding despite adjustments.
- Single metropolitan cohort may limit generalizability to other Latin American settings or rural populations.
Future Directions: Test targeted prevention programs for prediabetes with high adiposity and evaluate cost-effectiveness of HbA1c-based screening and interventions in Latin America.
BACKGROUND: Prediabetes has been associated with increased all-cause and cardiovascular mortality. However, no large-scale studies have been conducted in Mexico or Latin America examining these associations. METHODS: We analyzed data from 114 062 adults without diabetes (diagnosed or undiagnosed) from the Mexico City Prospective Study. Participants were followed until January 1, 2021, for cause-specific mortality. We defined prediabetes according to the American Diabetes Association (ADA; HbA1c ≥ 5.7% to <6.5%) and the International Expert Committee (IEC; HbA1c ≥ 6.0 to <6.5%) definitions. Cox regression adjusted for confounders was used to estimate all-cause and cause-specific mortality rate ratios (RR) for deaths occurring at ages 35 to 74 years associated with prediabetes. RESULTS: After median 18.4 (IQR 17.6-19.7) years of follow-up, individuals with prediabetes had higher risk of all-cause mortality at ages 35 to 74 compared to those without prediabetes (RR 1.13 [1.07-1.20] for ADA-defined and 1.27 [1.17-1.38] for IEC-defined prediabetes), as well as higher risk of cardiovascular (RR 1.23 [1.11-1.37] and 1.44 [1.24-1.67], respectively), renal (RR 1.33 [1.06-1.66] and 1.62 [1.18-2.23], respectively), and acute diabetic deaths (RR 2.62 [1.75-3.93] and 3.42 [2.09-5.61], respectively). The absolute excess risk associated with ADA-defined prediabetes at ages 35 to 74 accounted for 7% of cardiovascular, 9% of renal, and 31% of acute diabetic deaths. IEC-defined prediabetes accounted for 4%, 5% and 14% of cardiovascular, renal, and acute diabetic deaths. Prediabetes-associated excess mortality risks were, at least in part, explained by adiposity. CONCLUSION: Prediabetes is a significant risk factor for all-cause, cardiovascular, renal, and acute diabetic deaths in Mexican adults. Early identification and timely management of prediabetes among individuals at risk of this condition could reduce premature mortality in this population.